•  

Search Results for Johnson & Johnson

Blood Test for Depression

Investigators at CAMH and Indoc Research (formerly known as the Ontario Cancer Biomarker Network) are testing a new peripheral blood biomarker for major depressive disorder that may help to identify when a patient is experiencing or at risk of developing the disorder. The biomarker may also help researchers to develop new therapeutics for treating the […]

Read more

Ontario advancing nine medical research projects in cancer, heart disease and sleep apnea to market

Applications for next MSc PoP granting round being accepted until February 25, 2016 TORONTO (January 26, 2016) — Nine Ontario-based medical research projects built on great science with potential for significant economic impact are advancing a step closer to market entry thanks to funding from Ontario Centres of Excellence’s Medical Sciences Proof-of-Principle (MSc PoP) program. […]

Read more

Top 10 Portfolio Stories for 2015

2015 created a flurry of activity for MaRS Innovation and our portfolio. As the holidays begin, here are our picks for the top 10 news stories from MI’s portfolio in 2015. We look forward to more exciting developments in 2016. You may also have noticed we’ve refreshed our website and re-organized how we communicate about […]

Read more

Ontario Government Invests $1 Million in Toronto’s Neuroscience Catalyst Consortium

Ministry of Research & Innovation joins founding partners University of Toronto and Janssen Inc., and new partners Evotec AG, MaRS Innovation and Ontario Centres of Excellence, to advance treatments for neurological disorders and develop early-stage biotech companies TORONTO and PHILADELPHIA (June 16, 2015)— Toronto’s neuroscience efforts to find new drugs to treat and manage brain […]

Read more

Funding call: MaRS Innovation Industry Access Program (MI-IAP) accepting applications to February 6

Researchers working in orphan indications, immuno-oncology, respiratory diseases, diabetes, and other key areas invited to submit a brief Statement of Interest The MaRS Innovation Industry Access Program (MI-IAP) is a simple, formalized process for marketing early-stage technologies to MI’s industry partners: Baxter, LifeLabs (formerly CML Healthcare), GSK, Johnson & Johnson, Pfizer and IRICoR/Merck. The program’s […]

Read more

Portfolio Snapshot: Minuum debuts on Google Glass, Crowdmark named most innovative at SIIA

There’s been lots of activity in MI’s portfolio this week (and it’s only Wednesday). Read down for what you need to know about Whirlscape, Crowdmark, OtoSim, and ApneaDx. Whirlscape launches Google Glass demo video Whirlscape’s Minuum keyboard nabbed a four-star review from CNET’s editors only days before announcing their technology is now available for Google […]

Read more

MaRS Innovation Industry Access Program (MI-IAP) accepting applications until April 10

Researchers working in orphan indications, drug delivery devices, big data and other key areas invited to submit a brief Statement of Interest The MaRS Innovation Industry Access Program (MI-IAP) is a simple, formalized process for marketing early-stage technologies to MI’s industry partners: Baxter, LifeLabs (formerly CML Healthcare), GSK, Johnson & Johnson, Pfizer and Merck. The […]

Read more

MaRS Innovation’s 2013 Top 10 List

2013 was an exceptional year for MaRS Innovation. Here are the top 10 news stories from our commercialization portfolio. 1. MaRS Innovation secures a $15 million CECR funding extension In January, MaRS Innovation was one of four Centres of Excellence for Commercialization and Research to be successfully extended by the Networks of Centres of Excellence of Canada. This achievement […]

Read more

MaRS Innovation launches streamlined funding program

Applications invited for MI’s Industry Access Program, which matches early-stage, high-potential technologies to partners and funding MaRS Innovation (MI) has launched a unique funding program to match researchers with industry partners while advancing early stage technologies: the MaRS Innovation Industry Access Program (MI-IAP). This program provides a simple mechanism to connect researchers with MI’s industry partners. […]

Read more

Dr. Raphael Hofstein’s MRI blog post: How Team Ontario’s biotechnology takes on the world

Dr. Raphael (Rafi) Hofstein is president and CEO of MaRS Innovation (MI) – the commercialization agent for an exceptional research discovery pipeline stemming from 16 leading Ontario academic institutions. As a single entry point to annual member research and development activity of $1B, MI provides a gateway for investors and licensees who wish to access […]

Read more
Page 2 of 212